Healthcare acquired infection is acquired in hospital or other healthcare facilities. The infection is occurs due to prolonged hospital stay, disability, and economic burden. World health Organization estimates that every year hundreds of millions of patients around the world are affected by this infection.
The global hospital acquired infection diagnostics market is segmented based on infection type, test type, and region. Technological innovations in the diagnostics products is expected to propel the market growth. Rising increasing number of cases for hospital acquired infection especially in developing countries is expected to create demand for diagnostics products which in turn is expected support the market growth over the forecast period. Rapidly growing ageing population is other factor expected to drive the market.
Based on infection type, the market is segmented based on urinary tract infection (UTI), blood stream infection (BSI), surgical site infection (SSI), hospital acquired pneumonia, and others. The hospital acquired pneumonia segment contributes major market share over the forecast period.
Based on test type, the market is segment based on molecular diagnostics, and other in-vitro diagnostics tests. The molecular diagnostics segment contributes major market share and is expected to witness rapid growth rate over the forecast period owing to the technological advancements by manufacturers for molecular diagnostic test.
Do Inquiry of the Report Here: https://marketresearch.biz/report/hospital-acquired-infection-diagnostics-market/#inquiry
Based on region, the global hospital acquired infection diagnostics market is segmented into North America, Europe, Latin America, Asia Pacific and Middle East and Africa. North America contributes major market share and expected to maintain its dominance over the forecast period owing to favorable government initiatives in the region. Asia Pacific is expected to witness rapid growth rate over the forecast period. This is attributed to the increasing prevalence of hospital acquired infection and improving healthcare facilities in countries such as China and India.
Some prominent players in the global hospital acquired infection diagnostics market are Abbott Laboratories, AdvanDx, Inc., Alere, Inc., F. Hoffmann-La Roche AG, Becton, Dickinson and Company, Cepheid Inc., Seegene, Inc., bioMérieux SA, Merck & Company, Inc., and Meridian Bioscience, Inc.